Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- FDA Grants Priority Review to XTANDI for Add’l Indication: Astellas
May 8, 2014
- Takara Bio Submits IND Application for PII Study of Anticancer Agent HF10 to US FDA
May 8, 2014
- Drug Information Gained Mostly from Sales Reps, Less from Online Promotion: IMS Survey
May 8, 2014
- Nitto Denko Moving Ahead at Full Speed in Japan, US to Develop Nucleic Acid Drug as a Potential Cure for Cirrhosis
May 7, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
May 7, 2014
- Drug Makers’ Plans for MRs Becoming Clearer; Takeda to Bolster Force, Sanofi Making Big Reduction
May 7, 2014
- Ono, Nissan Chemical End Licensing Deal on Thrombocytopenia Agent
May 2, 2014
- Otsuka Granted European Approval for Multidrug-Resistant TB Medicine
May 2, 2014
- Oncolys Obtains Patent on Manufacturing Process for Anti-HIV Drug OBP-601 in Japan
May 2, 2014
- Nihon Chouzai Pharmaceutical Sales Reach 23,192 Million Yen in FY2013
May 1, 2014
- AZ Files for Domestic Approval of Bydureon Pen Formulation
May 1, 2014
- Chugai’s US Subsidiary Appoints Gianella-Borradori as Its Chief Medical Officer
May 1, 2014
- Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
- Daiichi Sankyo Ceases PIII Study of Nimotuzumab for Lung Cancer in Japan
April 30, 2014
- Takeda to Introduce New Performance-Based Incentive Programs for Board of Directors, Senior Execs
April 30, 2014
- Kissei Taps Morozumi as New President, COO
April 30, 2014
- Chugai Discontinues Multinational PIII of Onartuzumab for Lung Cancer
April 30, 2014
- Hisamitsu Begins PI of Transdermal Schizophrenia Treatment in US
April 30, 2014
- Novel Anticancer Agent Trabectedin Meets Primary Endpoint of PFS in PII: Taiho
April 25, 2014
- MTPC Names Masayuki Mitsuka as New President
April 24, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…